SEC Info - Boston Scientific Corp. - ‘8-K’ for 5/6/21

SEC Info℠

Home

Help

Please Sign In

Boston Scientific Corp. – ‘8-K’ for 5/6/21

On: Tuesday, 5/11/21, at 4:49pm ET · For: 5/6/21 · Accession #: 885725-21-16 · File #: 1-11083

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/11/21  Boston Scientific Corp.           8-K:5,9     5/06/21   12:239K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         8-K May 11, 2021                                    HTML     35K 
 8: R1          Cover Document                                      HTML     53K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- bsx-20210506_htm                    XML     30K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.CAL  XBRL Calculations -- bsx-20210506_cal                XML      7K 
 4: EX-101.DEF  XBRL Definitions -- bsx-20210506_def                 XML     41K 
 5: EX-101.LAB  XBRL Labels -- bsx-20210506_lab                      XML     87K 
 6: EX-101.PRE  XBRL Presentations -- bsx-20210506_pre               XML     42K 
 2: EX-101.SCH  XBRL Schema -- bsx-20210506                          XSD     13K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    21K 
12: ZIP         XBRL Zipped Folder -- 0000885725-21-000016-xbrl      Zip     17K

‘8-K’ — 8-K May 11, 2021

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

bsx-20210506

i 0000885725 i false00008857252021-05-062021-05-060000885725us-gaap:CommonStockMember2021-05-062021-05-060000885725bsx:SeniorNotedue2027Member2021-05-062021-05-060000885725bsx:A550MCPSSeriesAMember2021-05-062021-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________________

FORM i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): May 11, 2021 ( i May 6, 2021)

i BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

i Delaware

i 1-11083

i 04-2695240

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

i 300 Boston Scientific Way, i Marlborough, i Massachusetts i 01752-1234

(Address of principal executive offices) (Zip Code)

( i 508) i 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


i ☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

i Common Stock, $0.01 par value per share

i BSX

i New York Stock Exchange

i 0.625% Senior Notes due 2027

i BSX27

i New York Stock Exchange

i 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share

i BSX PR A

i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

a.The Company held the Annual Meeting on May 6, 2021 in a virtual-only format via live audio webcast.

b.The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

1.All nine director nominees were elected to the Board for a one-year term to hold office until the Company’s 2022 Annual Meeting of Stockholders and until their successors have been elected and qualified.


Nominee	For	Withheld	Broker Non-Votes
Nelda J. Connors	1,177,891,538	23,153,746	35,942,800
Charles J. Dockendorff	1,180,325,305	20,719,979	35,942,800
Yoshiaki Fujimori	924,740,926	276,304,358	35,942,800
Donna A. James	1,181,664,255	19,381,029	35,942,800
Edward J. Ludwig	1,192,357,593	8,687,691	35,942,800
Michael F. Mahoney	1,138,411,568	62,633,716	35,942,800
David J. Roux	1,074,889,476	126,155,808	35,942,800
John E. Sununu	1,179,506,731	21,538,553	35,942,800
Ellen M. Zane	1,194,525,658	6,519,626	35,942,800

2.The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting was approved.


For	Against	Abstain	Broker Non-Votes
1,111,007,103	89,153,248	884,933	35,942,800

3.The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2021 fiscal year was ratified.


For	Against	Abstain
1,186,049,676	50,339,971	598,437

4.The stockholder proposal requesting a report to stockholders describing any benefits to the Company related to employee participation in Company governance was not approved.


For	Against	Abstain	Broker Non-Votes
55,609,263	1,143,836,828	1,599,193	35,942,800

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits


Exhibit No.						Description
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

May 11, 2021

BOSTON SCIENTIFIC CORPORATION

By:

/s/ Vance R. Brown

Vance R. Brown

Vice President and Chief Corporate Counsel